OSCR

Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain Metastases.

Overview

  1. Department of Pathology, University of Colorado Anschutz, Aurora, Colorado
  2. Department of Neurosurgery, University of Colorado Anschutz, Aurora, Colorado
  3. Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz, Aurora, Colorado
  4. Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz, Aurora, Colorado
Institutions: University of Colorado Anschutz (United States)
Journal: Cancer research communications, volume 6, issue 8, pages 1850-1861
Dates: received 22 December 2025; accepted 20 July 2026; published online 4 August 2026; in print August 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.1158/2767-9764.crc-25-0811 · PMID 42480609 · PMCID PMC13436848 · OpenAlex W7169878855
Open access: gold, a free copy (OpenAlex)
Categories: human (organism), mouse (organism), other condition (population), cellular / molecular (subfield)
Methods: Statistics, Evoked potentials, fMRI & imaging
MeSH: Brain Neoplasms*, Lung Neoplasms*, Membrane Glycoproteins*, Protein Kinase Inhibitors*, Receptor, trkA*, Receptor, trkB*, Animals, Benzamides, Brain-Derived Neurotrophic Factor, Cell Line, Tumor, Cell Proliferation, Humans, Indazoles, Mice, Signal Transduction, Tyrosine Kinase Inhibitors (* major topic)
Topic: Brain Metastases and Treatment (Oncology, Medicine), according to OpenAlex
Funding: NIH Office of the Director (OD) (NIH S10 OD027023); NCI NIH HHS (P30 CA046934, R37 CA227984); University of Colorado School of Medicine, Anschutz Medical Campus (CU School of Medicine) (Thoracic research initiative pilot funding); NIH HHS (S10 OD027023); National Cancer Institute (NCI) (R37CA227984, P30CA046934)
Citations: not cited yet (Europe PMC); 46 references in the paper
Research resources: Human NSCLC cell lines LU65 RRID:CVCL_1392, H358 RRID:CVCL_1559, The murine NSCLC cell line CMT167 RRID:CVCL_2405, RRID:SCR_021980

Abstract

The central nervous system (CNS) is a common site of metastasis for both non–small cell and small cell lung cancer, yet the therapeutic strategies to prevent and decrease lung cancer brain metastases (BM) remain limited. Tyrosine kinase inhibitors have shown promising results in increasing overall response in BM, owing to their brain penetrance and increased effectiveness; however, their use is limited to a small group of tumors carrying specific oncogenic drivers. Among these, inhibitors targeting neurotrophic tyrosine receptor kinases (NTRK) are showing promising effects in reducing CNS metastases in cancers driven by gene rearrangements of these drugs’ targets. However, wild-type NTRKs are susceptible to activation by their canonical ligands, which are expressed throughout the BM niche and can, in a paracrine manner, activate NTRK function in cancer cells. In this study, we show that NTRKs are expressed in primary tumors, BM, and lung cancer cells with various driver mutations expressing wild-type NTRK2 (WT-TrkB). We demonstrate that WT-TrkB activates downstream signaling and proliferation in response to exogenous brain-derived neurotrophic factor (BDNF) and conditioned media from reactive astrocytes known to secrete BDNF in the brain niche. Importantly, the FDA-approved NTRK inhibitor entrectinib blocked BDNF and astrocyte-induced survival pathways in multiple lung cancer cell lines, decreased their proliferation in vitro, and effectively prevented BM colonization and progression in vivo without significant effects on extracranial disease. Thus, these studies suggest that brain-dependent activation of NTRK is critical for BM of WT-NTRK+ lung cancers; therefore, NTRK inhibitors can be used to target nonfusion NTRK function to prevent or decrease BM.

Significance: These studies demonstrate that NTRK wild-type receptors are important drivers of brain metastatic colonization and progression in different subtypes of lung cancer, independent of their driver alterations. Thus, they provide a rationale to expand the use of FDA-approved NTRK inhibitors with brain penetrance for the prevention of CNS metastases.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Data Availability

All data and protocols described in the article will be made available upon reasonable request within 6 years of publication.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 10 authors, 16 MeSH terms, 5 funders, 46 references, 4 RRIDs.

Cite

This paper

Contreras-Zárate, M. J., Jaramillo-Gómez, J. A., Marquez-Ortiz, R. A., Pham, T. C., Koliavas, S. N., Ormond, D. R., Navarro, A. C., Nemenoff, R. A., Camidge, D. R., & Cittelly, D. M. (2026). Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain Metastases. Cancer research communications, 6(8), 1850-1861. https://doi.org/10.1158/2767-9764.crc-25-0811

BibTeX

@article{contreraszarate2026targeting,
author = {Contreras-Zárate, Maria J and Jaramillo-Gómez, Jenny A and Marquez-Ortiz, R Alejandro and Pham, Trinh C and Koliavas, Stella N and Ormond, D Ryan and Navarro, Andre C and Nemenoff, Raphael A and Camidge, D Ross and Cittelly, Diana M},
title = {{Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain Metastases}},
journal = {Cancer research communications},
year = {2026},
month = aug,
volume = {6},
number = {8},
pages = {1850--1861},
publisher = {American Association for Cancer Research},
issn = {2767-9764},
doi = {10.1158/2767-9764.crc-25-0811},
url = {https://doi.org/10.1158/2767-9764.crc-25-0811},
pmid = {42480609},
pmcid = {PMC13436848}
}

RIS

TY - JOUR
AU - Contreras-Zárate, Maria J
AU - Jaramillo-Gómez, Jenny A
AU - Marquez-Ortiz, R Alejandro
AU - Pham, Trinh C
AU - Koliavas, Stella N
AU - Ormond, D Ryan
AU - Navarro, Andre C
AU - Nemenoff, Raphael A
AU - Camidge, D Ross
AU - Cittelly, Diana M
TI - Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain Metastases
T2 - Cancer research communications
J2 - Cancer Res Commun
PY - 2026
DA - 2026/08/01
VL - 6
IS - 8
SP - 1850
EP - 1861
SN - 2767-9764
PB - American Association for Cancer Research
DO - 10.1158/2767-9764.crc-25-0811
UR - https://doi.org/10.1158/2767-9764.crc-25-0811
LA - en
ER -

CSL-JSON

{
"id": "10.1158/2767-9764.crc-25-0811",
"type": "article-journal",
"title": "Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain Metastases",
"container-title": "Cancer research communications",
"author": [
{
"family": "Contreras-Zárate",
"given": "Maria J"
},
{
"family": "Jaramillo-Gómez",
"given": "Jenny A"
},
{
"family": "Marquez-Ortiz",
"given": "R Alejandro"
},
{
"family": "Pham",
"given": "Trinh C"
},
{
"family": "Koliavas",
"given": "Stella N"
},
{
"family": "Ormond",
"given": "D Ryan"
},
{
"family": "Navarro",
"given": "Andre C"
},
{
"family": "Nemenoff",
"given": "Raphael A"
},
{
"family": "Camidge",
"given": "D Ross"
},
{
"family": "Cittelly",
"given": "Diana M"
}
],
"container-title-short": "Cancer Res Commun",
"volume": "6",
"issue": "8",
"page": "1850-1861",
"DOI": "10.1158/2767-9764.crc-25-0811",
"PMID": "42480609",
"PMCID": "PMC13436848",
"ISSN": "2767-9764",
"publisher": "American Association for Cancer Research",
"URL": "https://doi.org/10.1158/2767-9764.crc-25-0811",
"language": "en",
"issued": {
"date-parts": [
[
2026,
8,
1
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1038/s41467-026-73726-5
Brain FGF2 and NCAM1 contribute to FGFR1-dependent progression of estrogen receptor-positive breast cancer brain metastases.
Journal: Nature communications
In common: other condition, mouse, cellular / molecular, 5 references, 4 authors
[2] doi:10.1186/s43556-025-00251-0
Cancer brain metastasis: molecular mechanisms and therapeutic strategies.
Journal: Molecular biomedicine
In common: other condition, 4 references
[3] doi:10.1038/s41467-025-60466-1 [code]
Towards fair decentralized benchmarking of healthcare AI algorithms with the Federated Tumor Segmentation (FeTS) challenge.
Journal: Nature communications
In common: other condition, author D Ryan Ormond
[4] doi:10.1038/s41591-022-01749-8
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.
Journal: Nature medicine
In common: other condition, 3 references
[5] doi:10.64898/2025.12.10.693579 [code]
Serotonergic neuron-glioma interactions drive high-grade glioma pathophysiology
Journal: bioRxiv (preprint)
In common: other condition, cellular / molecular, 3 references
[6] doi:10.1158/1535-7163.mct-25-0025
Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations.
Journal: Molecular cancer therapeutics
In common: other condition, mouse, 2 references
[7] doi:10.1038/s41417-024-00809-0
Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene.
Journal: Cancer gene therapy
In common: other condition, cellular / molecular, 2 references
[8] doi:10.1007/s11538-025-01557-4 [code]
Astrocyte Reprogramming Drives Tumor Progression and Chemotherapy Resistance in Agent-Based Models of Breast Cancer Brain Metastases.
Journal: Bulletin of mathematical biology
In common: other condition, cellular / molecular, 2 references
[9] doi:10.7150/thno.122241
CD146<sup>+</sup> pericyte-like lung cancer brain metastatic stem cells promote tumor angiogenesis through dual regulatory effects on the VEGF/VEGFR axis.
Journal: Theranostics
In common: other condition, mouse, cellular / molecular, 2 references
[10] doi:10.1126/scitranslmed.adu2459
A genome-wide in vivo CRISPR activation screen identifies BACE1 as a therapeutic vulnerability of lung cancer brain metastasis.
Journal: Science translational medicine
In common: other condition, mouse, cellular / molecular, 2 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.